San Mateo, Calif. – January 8, 2024 – PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the early detection, treatment selection and recurrence monitoring of cancer and other complex diseases – today announced promising results from the largest, deep multi-omics study conducted to date. The study, published online in medRxiv, focused on subjects at risk for lung cancer, demonstrating the power of multi-omics to deliver both high sensitivity and high specificity in the detection of early-stage lung cancer.
Read the full article here.
January 23, 2023
PrognomiQ’s Multi-omics Liquid Biopsy Platform Demonstrates Promising Results in Early-Stage Cancer Detection of Non-Small Cell Lung Cancer
Read More
November 29, 2022
PrognomiQ Strengthens its Scientific and Clinical Leadership with the Appointment of Brian Koh, M.D. as Chief Medical Officer
Read More